바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.71 No.6
Citation Share

Sarcoidosis Induced by Adalimumab in Rheumatoid Arthritis

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2011, v.71 no.6, pp.464-469











& (2011). Sarcoidosis Induced by Adalimumab in Rheumatoid Arthritis. Tuberculosis & Respiratory Diseases, 71(6), 464-469.
  • Downloaded
  • Viewed
PDF Download

Abstract

Adalimumab is a full human monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-α). This has recently been shown to be effective in the treatment of rheumatoid arthritis (RA), ankylosing spondylitis, and other conditions. Sacoidosis is known to be the target for adalimumab but we describe a patient who has developed sarcoidosis with lung involvement during adalimumab therapy for RA. A 48-year-old woman, who was treated with adalimumab for 5 months, was admitted because of chronic cough and both hilar lymphadenopathy on chest radiography. Chest computed tomography revealed the enlargement of multiple lymph nodes in the right supraclavicular, subcarinal, both hilar and right axillary area. She was diagnosed with sarcoidosis based on the biopsy of supraclavicular lymph node, skin and lung through video-associated thoracoscopic surgery, which was non-caseating epitheloid cell granuloma and excluded from a similar disease. She was treated for sarcoidosis with prednisolone and methotrexate instead of adalimumab.

keywords
Tumor Necrosis Factor-alpha, Antibodies, Monoclonal, Humanized, Sarcoidosis, Arthritis, Rheumatoid

Reference

1.

1. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011;13 Suppl 1:S5.

2.

2. Senolt L, Vencovský J, Pavelka K, Ospelt C, Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009;9:102-7.

3.

3. Lahmer T, Knopf A, Lanzl I, Heemann U, Thuermel K. Using TNF-alpha antagonist Adalimumab for treatment for multisystem sarcoidosis: a case study. Rheumatol Int 2011 Jun 5 [Epub]. DOI: 10.1007/s00296-011-1968-x.

4.

4. Javot L, Tala S, Scala-Bertola J, Massy N, Trenque T, Baldin B, et al. Sarcoïdosis and anti-TNF: a paradoxical class effect? Analysis of the French pharmacovigilance system database and literature review. Therapie 2011;66:149-154.

5.

5. Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 2008;26:471-5.

6.

6. Clementine RR, Lyman J, Zakem J, Mallepalli J, Lindsey S, Quinet R. Tumor necrosis factor-alpha antagonist-induced sarcoidosis. J Clin Rheumatol 2010;16:274-9.

7.

7. Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc) 2011;47:277-88.

8.

8. Pink AE, Fonia A, Smith CH, Barker JN. The development of sarcoidosis on antitumour necrosis factor therapy: a paradox. Br J Dermatol 2010;163:648-9.

9.

9. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010; 9:188-93.

10.

10. Kerjouan M, Jouneau S, Lena H, Luraine R, Desrues B, Delaval P. Pulmonary sarcoidosis developing during treatment with etanercept. Rev Mal Respir 2011;28: 360-4.

11.

11. Gifre L, Ruiz-Esquide V, Xaubet A, Gómez-Puerta JA, Hernández MV, Sanmartí R. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case pre sentation and a literature review. Arch Bronconeumol 2011;47:208-12.

12.

12. Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 2008;26:471-5.

13.

13. Daïen CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009; 48:883-6.

14.

14. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153-65.

15.

15. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006;36:159-67.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy